New injection aims to tame dangerous pregnancy condition
NCT ID NCT07282171
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a single injection of CBP-4888 in 60 pregnant women hospitalized with preterm preeclampsia, a serious condition involving high blood pressure and organ stress. The goal is to find a safe dose and see if the drug can lower a harmful protein called sFlt1. Participants receive standard care plus the study drug, and both mothers and babies are followed for months after delivery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CBP-4888 (a drug given as a single injection under the skin)
What this could lead to
If it works, this could lead to a new treatment that helps manage preterm preeclampsia by lowering a harmful protein in the blood, potentially allowing safer continuation of pregnancy.
What could go wrong
This is an early Phase 1 trial with only 60 participants, so safety and effectiveness are not yet proven. The drug may not lower the protein enough or could cause unexpected side effects in mothers or babies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREECLAMPSIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Monash University
RECRUITINGMelbourne, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal Melbourne
RECRUITINGMelbourne, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Royal Women's Hospital
RECRUITINGParkville, Victoria, 3052, Australia
Contact Email: •••••@•••••